Clinical trials: Pelvis Disease
Pelvic Floor Disorders
Combination Treatment With BTL-899 and HPM-6000UF Devices
This study will evaluate the clinical efficacy of the BTL-899 and HPM-6000UF devices in combination for non-invasive strengthening of the core muscles and overall improvement in quality of life in elderly patients.
- Trial name
- NCT05537181
- Testing
- BTL-899; HPM-6000UF Treatments
- Where
- 3 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Ovarian Cancer
Risk of Ovarian Cancer in Patients With a Pelvic Mass
The purpose of this clinical trial is to evaluate the ability of multiple serum biomarkers to estimate the risk of ovarian cancer in women presenting with pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic…
- Trial name
- NCT00315692
- Testing
- Biomarker Assay (CA125 and HE4)
- Where
- 2 sites in United States
- Volunteers
- 566 people
- Sponsor
- Fujirebio Diagnostics, Inc.
Painful Bladder Syndrome, Interstitial Cystitis
Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis
A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.
- Conditions
- Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT00517868
- Testing
- URG101
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Urigen
Pelvic Organ Prolapse
Exair® Versus Native Tissue Repair for Prolapse
The purpose of this study is to compare safety and effectiveness of the Exair Prolapse Repair System for treatment of pelvic organ prolapse to traditional native tissue repair through 36 months of follow-up.
- Trial name
- NCT02162628
- Testing
- Exair Prolapse Repair System, Total Native Tissue Repair
- Where
- 14 sites in United States, Canada
- Volunteers
- 79 people
- Sponsor
- Coloplast A/S
Endometriosis Related Pain
SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on…
- Trial name
- NCT03204331
- Testing
- Relugolix, Estradiol/norethindrone acetate
- Where
- 91 sites in United States, Australia and 9 more
- Volunteers
- 623 people
- Sponsor
- Myovant Sciences GmbH
Prostate Cancer, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
- Trial name
- Solar-Stage (NCT06235151)
- Testing
- Copper Cu 64 PSMA I&T
- Where
- 43 sites in United States
- Volunteers
- 439 people
- Sponsor
- Curium US LLC
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the…
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-103 (NCT03288545)
- Testing
- enfortumab vedotin (EV), pembrolizumab, cisplatin
- Where
- 106 sites in United States, Canada and 4 more
- Volunteers
- 348 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Endometriosis
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have…
- Trial name
- EDELWEISS 5 (NCT04372121)
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Female Urogenital Diseases, Urinary Incontinence
Clinical Trial of "Magic Gyno" Laser Device
The aim of this prospective study is investigation of efficiency and safety of medical device "Magic Gyno" in accordance with the stated purpose.
- Conditions
- Female Urogenital Diseases, Urinary Incontinence, Prolapse Genital, Menopausal Syndrome
- Trial name
- NCT05463081
- Testing
- Laser treatment, Blood test, Clinical urine test
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- MeLSyTech, Ltd
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Osteoarthritis, Tendinitis
Evaluation of Outcomes With Umbilical Cord Allograft for Musculoskeletal Conditions Musculoskeletal Conditions
The aim of the study is to determine the efficacy of an Amniotic Fluid Tissue Product for pain relief and functional improvements for all types of musculoskeletal conditions.
- Conditions
- Osteoarthritis, Tendinitis, Sports Injury, Degenerative Disc Disease
- Trial name
- NCT03390920
- Testing
- Umbilical Allograft
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- R3 Stem Cell
Endometriosis
A Long-Term Study to Evaluate the Safety of Asoprisnil in the Treatment of Women With Endometriosis From Study M01-398
The objective of this study is to determine the long-term safety of asoprisnil 5 mg for 12 months in women with endometriosis from study M01-398.
- Trial name
- NCT00160420
- Testing
- Asoprisnil
- Volunteers
- 73 people
- Sponsor
- Abbott